LIQUIDIA CORP (LQDA)
Health Care · Rare disease biopharmaceuticals / respiratory therapeutics · NASDAQ
Liquidia is a rare-disease biopharmaceutical company commercializing YUTREPIA, a next-generation inhaled treprostinil with proprietary particle engineering, for pulmonary hypertension.
What LIQUIDIA CORP does
Liquidia is a biopharmaceutical company focused on respiratory and vascular diseases, primarily pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company commercializes YUTREPIA (treprostinil inhalation powder), approved by the FDA in May 2025, along with a profit-sharing agreement on generic treprostinil injection with Sandoz. Liquidia is also developing L606, a liposomal treprostinil formulation, and exploring YUTREPIA for additional indications including PH-COPD, IPF, and Raynaud's phenomenon.
Themes: ["Pulmonary arterial hypertension (PAH) treatment","Pulmonary hypertension / interstitial lung disease (PH-ILD)","Respiratory drug delivery / inhalation therapies","Orphan/rare disease","Prostacyclin pathway therapeutics"]
Fundamentals
- Price$81.45 as of 2026-07-09 close
- Market cap$7.2B as of 2026-07-10
- 1-year return+504.2% as of 2026-07-09 close
- P/E324.73 as of 2026-07-10
- Net margin+7.7% as of 2026-07-10
- Gross margin+91.8% as of 2026-07-10
- ROE+46.8% as of 2026-07-10
- Debt / equity1.64 as of 2026-07-10
- Revenue growth (YoY)+1936.7% as of 2026-07-10
- Revenue CAGR (3y)+115.0% SEC XBRL
- Beta0.58 as of 2026-07-10
Key risks (from latest filing)
["Sustained revenue generation uncertain despite YUTREPIA FDA approval and recent commercialization launch in June 2025; accumulated deficit of $573.5 million and history of significant operating losses","Competitive pressure from other approved PAH and PH-ILD therapies targeting different pathways (nitric oxide, endothelin, activin signaling), as well as other inhaled treprostinil formulations already on market","Clinical development risk for L606 and YUTREPIA expansion into additional indications (PH-COPD, IPF, PPF, SSc-RP); outcome of pivotal studies and regulatory approval uncertain"]
Competitors & peers
- Actelion (Janssen, now part of Johnson & Johnson) - PAH therapies
- Gilead Sciences - PAH and PH-ILD inhaled treprostinil (Tyvaso)
- United Therapeutics - PAH and PH-ILD therapies
- Merck - PAH and PH-ILD therapies
- Bayer - PAH endothelin pathway inhibitors
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.